Who are Xolair's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Xolair, ANTI-IGE THERAPY (XOLAIR), Xolair injections, Xolair® + Symbicort®, Xolair Prefilled Syringe.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/omalizumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Xolair — Competitive Intelligence Brief

Xolair (omalizumab) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anti-IgE [EPC]. Area: Immunology.

marketed Anti-IgE [EPC] Ig epsilon chain C region Immunology Live · refreshed every 30 min

Target snapshot

Xolair (omalizumab) — Roche.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Xolair TARGET	omalizumab	Roche	marketed	Anti-IgE [EPC]	Ig epsilon chain C region
Xolair	Xolair	Taizhou Mabtech Pharmaceutical Co.,Ltd	marketed		Ig epsilon chain C region
ANTI-IGE THERAPY (XOLAIR)	ANTI-IGE THERAPY (XOLAIR)	Children's Hospital of The King's Daughters	marketed	Anti-IgE monoclonal antibody	Immunoglobulin E (IgE)
Xolair injections	Xolair injections	University of California, Los Angeles	marketed	Anti-IgE monoclonal antibody	Immunoglobulin E (IgE)
Xolair® + Symbicort®	Xolair® + Symbicort®	AO GENERIUM	phase 3	Anti-IgE antibody and corticosteroid/long-acting beta2-adrenergic receptor agonist combination	IgE receptor
Xolair Prefilled Syringe	Xolair Prefilled Syringe	Kashiv BioSciences, LLC	phase 3	Monoclonal antibody (anti-IgE)	Immunoglobulin E (IgE)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anti-IgE [EPC] class)

Roche · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Xolair — Competitive Intelligence Brief. https://druglandscape.com/ci/omalizumab. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab